This study aims to determine the improvement of financial performance during the pandemic in the pharmaceutical sector listed on the Indonesia Stock Exchange (IDX). The approach method used is a quantitative descriptive approach. The type of data used is secondary data obtained from the Indonesia Stock Exchange, namely the financial statements of the Pharmaceutical Sub-Sector Companies from 2019 to 2020. The ratio analysis used in this study includes analysis of liquidity, solvency, activity and profitability ratios, as well as additional ratios from researchers. The previous ones are growth ratio and valuation ratio. The results of the study show that the liquidity ratio of the financial power of PT Merck Indonesia Tbk for the 2019-2020 period is intended for the current ratio to absorb a share in the size, which is quite helpful in balancing the addition of other pharmaceutical companies. The solvency ratio of PT Kalbe Farma Tbk's financial power for the 2019-2020 period intended that the debt to asset ratio absorb the helping measure, and the debt to equity ratio absorb the helping measure because it has a low excess profit. The profitability ratio of PT Kalbe Farma Tbk's financial power in the era of The 2019-2020 period represents the return on assets (ROA) as part of the supporting measure, and the return on equity (ROE) absorbs the part in the said-help measure, although the start of the 2020 period is likely to undergo a downturn. The ratio of progress to the financial power of PT Indo Farma Tbk in the 2019-2020 period was also followed by PT. Kalbe Farma Tbk designates sales progress through an increase in life, genuine benefit progress through a downturn, and an increase in sales progress through an increasing life, although listed companies have the opportunity to go through a downturn, they can still live a life of good progress.